National Comprehensive Cancer Network



NCCN Oncology Research Program (ORP)
ORP Recent News
ORP Affiliate Research Consortium
ORP Scientific Publications
ORP for Industry
ORP Investigator Steering Committee
ORP Testimonials
Clinical Trials at NCCN Member Institutions
Find NCCN ORP Funded Clinical Trials at NCCN Member Institutions
ORP Grant History
Informed Consent Language Database
Points to Consider on the Best Practices for Biorepositories, Registries and Databases
NCCN Shared Resources (Members Only
ORP Disclosure Policy
Call for Abstracts: NCCN General Poster Session
NCCN Collaboration with the National Business Group on Health
NCCN Health Information Technology Licensees

NCCN Research & Business Resources

Ixabepilone added to Uterine Neoplasms Guideline; Cervical Cancer Guideline Also Updated

The NCCN Clinical Practice Guidelines in Oncology™ for Uterine Neoplasms have been updated to v.1.2010. For patients with recurrent, metastatic, or high-risk endometrial carcinoma, systemic therapy with ixabepilone as a single agent was added as a second line option. This recommendation is listed as Category 2B.

The NCCN Clinical Practice Guidelines in Oncology™ for Cervical Cancer have also been updated and published by NCCN as v.1.2010.